Home Search Abstracts Browse Oral Sessions Browse Poster Sessions

 

Session 195-Poster Abstracts
Clinical and Modeling Studies of Oral and Topical PrEP
Monday, 2-4 pm; Hall B
      990 A Phase 1 Randomized Controlled Trial of a Triple Anti-HIV-1 Monoclonal Antibody Vaginal Microbicide
Georgina Morris*1, R Wiggins1, S Woodhall1, C Taylor2, B Vcelar3, M Bland1, and C Lacey1
1Univ of York, UK; 2York Hosp, UK; and 3Polymun Sci, Vienna, Austria
      991 Genital Tract Inflammation in Women Participating in the CAPRISA TFV Microbicide Trial Who Became Infected with HIV: A Mechanism for Breakthrough Infection?
Lindi Roberts*1, J-A Passmore1,2, C Williamson1,3, F Little1, V Naranbhai3, S Sibeko3, G Walzl4, Q Abdool Karim3,5, and S Abdool Karim3,5
1Univ of Cape Town, South Africa; 2Natl Hlth Lab Svc, Cape Town, South Africa; 3Ctr for the AIDS Prgm of Res in South Africa, Durban; 4Stellenbosch Univ, Cape Town, South Africa; and 5Columbia Univ, New York, NY, US
      992 ARV for HIV Prevention: DRV + Low-dose RTV and ETR Exposure in the Rectal Tissue and Seminal Plasma of Healthy Male Volunteers after Single and Multiple Dosing
Kevin Brown*, K Patterson, S Jennings, N Shaheen, H Prince, M Spacek, M Cohen, and A Kashuba
Univ of North Carolina at Chapel Hill, US
      993 Comparison of 3 Rectal Douches as Safe, Preferred Delivery Vehicle for Rectal Microbicides
F Leyva1, E Fuchs1, A Ventuneac2, A Carballo-Dieguez3, L Lee1, M Torbenson1, L Li1, and Craig Hendrix*1
1Johns Hopkins Univ, Baltimore, MD, US; 2Ctr for HIV Ed Studies and Training, Hunter Coll of the City Univ of New York, NY, US; and 3Columbia Univ, Coll of Physicians & Surgeons, New York, NY, US
      994

 Enrollment Characteristics, Follow Up, Risk Behavior, and Assessing Adherence of IDU in a PrEP Prophylaxis Trial in Bangkok
Michael Martin*1,2, S Vanichseni3, P Suntharasamai3, U Sangkum3, R Chuachoowong1, P Mock1, M Leethochawalit4, S Chiamwongpaet4, S Kittimunkong5, K Choopanya3, and Bangkok Tenofovir Study Group
1Thailand Ministry of Publ Hlth-US CDC Collaboration, Nonthaburi; 2CDC, Atlanta, GA, US; 3Bangkok Tenofovir Study Group, Thailand; 4Bangkok Metropolitan Admin, Thailand; and 5Thailand Ministry of Publ Hlth, Nonthaburi
      995

 Validating Hair as a Biological Marker of TFV Drug Exposure in HIV PrEP
Albert Liu*1,2, M Gandhi2, P Bacchetti2, Y Huang2, P Anderson3, K Goggin4, S Buchbinder1,2, R Grant2,5, and R Greenblatt2
1San Francisco Dept of Publ Hlth, CA, US; 2Univ of California, San Francisco, US; 3Univ of Colorado Denver, Aurora, US; 4Univ of Missouri, Kansas City, US; and 5Gladstone Inst of Virology and Immunology, San Francisco, CA, US
      996

 Rectal Microbicides in the Prevent HIV Infection in Heterosexual Populations in High-prevalence Settings
Dobromir Dimitrov*1, M-C Boily2, S Abdool Karim3, and B Mâsse1,4
1Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 2Imperial Coll London, UK; 3Univ of KwaZulu-Natal, Durban, South Africa; and 4Univ of Montreal, Canada
      997 Combination HIV Pprevention for MSM in Concentrated and Generalized Epidemics: Modeling the Impacts of HIV Prevention Interventions for MSM in Peru and Kenya
A Wirtz1, D Walker1, S Baral1, F Sifakis1, B Johns1, L Bollinger2, and Chris Beyrer*1
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and 2Futures Inst, Glastonbury, CT, US
      998

 What Impact Would Introduction of a TDF Vaginal Microbicide Have on Incidence of HIV in Women and Men in Southern Africa?
Valentina Cambiano*1, D Bennett1, G Garnett2, J Lundgren3, D Pillay1, A Miners4, M Vitoria1, and A Phillips1
1Univ Coll London, UK; 2Imperial Coll London, UK; 3Univ of Copenhagen, Denmark; and 4London Sch of Hygiene and Tropical Med, UK
      999 How Much of the Overall Microbicide Effectiveness against HIV Is Due to the Protection of TFV Gel against HSV-2? The CAPRISA-004 Trial
M-C Boily1, Dobromir Dimitrov*2, and B Mâsse3
1Imperial Coll London, UK; 2Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; and 3Ctr Hosp Univ Ste-Justine Res Ctr, Montreal, Canada
    1000 Knowledge, Attitudes, and Beliefs of Massachusetts Physicians Regarding Topical and Oral Antiretroviral Chemoprophylaxis
Kenneth Mayer*1,2, M Mimiaga1,3,4, J White1, D Krakower3,5, and R Vanderwarker1
1Fenway Community Hlth, Boston, MA, US; 2Brown Univ, Providence, RI, US; 3Harvard Med Sch, Boston, MA, US; 4Harvard Sch of Publ Hlth, Boston, MA, US; and 5Beth Israel Deaconess Med Ctr, Boston, MA, US
    1001 Pharmacokinetic and Safety Assessment of Monthly Anti-HIV DPV Vaginal Microbicide Rings with Multiple Dosing
Annalene Nel*, S Habibi, S Smythe, J Nuttall, and P Lloyd
International Partnership for Microbicides, Silver Spring, MD, USA
    1002 Oral TDF and Its Impact in HSV-2 Acquisition and Clinical Expression
Javier Lama*1, K Mayer2, M Schechter3, E Kallas4, L-G Bekker5, S Chariyalertsak6, S Shiboski7, R Grant7,8, and iPrEx Study Team
1Investigaciones Medicas en Salud and Assn Civil Impacta Salud y Ed, Lima, Peru; 2Fenway Hlth, Boston, MA, US; 3Federal Univ of Rio de Janeiro, Brazil; 4Univ of Sao Paulo Sch of Med, Brazil; 5Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa; 6Res Inst for Hlth Sci, Chiang Mai Univ, Thailand; 7Univ of California, San Francisco, US; and 8Gladstone Inst of Virology and Immunology, San Francisco, CA, US
    1003 An EVA Vaginal Ring Containing the NNRTI MIV-150 Protects against SHIV-RT Infection in vivo
Rachel Singer*1, N Derby1, P Mawson1, J Lifson2, M Piatak2, J Fernandez-Romero1, T Zydowsky1, A Gettie3, J Blanchard4, and M Robbiani1
1Population Council, New York, NY, US; 2SAIC-Frederick, Inc, NCI-Frederick, MD, US; 3Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; and 4Tulane Natl Primate Res Ctr, Covington, LA, US
    1004

 Safety and Acceptability of Silicone Elastomer Vaginal Rings as Potential Microbicide Delivery Method in African Women
Annalene Nel*1, K Young1, J Romano1, C Woodsong1, E Montgomery2, G Masenga3, H Rees4, L-G Bekker5, and S Ganesh6
1Intl Partnership for Microbicides, Silver Spring, MD, US; 2Res Triangle Inst, San Francisco, CA, US; 3Kilimanjaro Christian Med Ctr, Moshi, Tanzania; 4Reproductive Hlth and HIV Res Unit, Johannesburg, South Africa; 5Desmond Tutu HIV Fndn, Cape Town, South Africa; and 6MRC, Durban, South Africa